Saturday 26 May 2018

Common eye drug may treat baldness

Scientists may have found a new way to treat baldness thanks to a side effect of a common eye drug
Scientists may have found a new way to treat baldness thanks to a side effect of a common eye drug

A side effect of a common eye drug could lead to its use as a baldness treatment, say researchers.

Lumigan is administered as eye drops to patients with glaucoma, a condition caused by excess fluid in the eye that leads to vision loss, but it has one marked side effect - it can stimulate the growth of eyelashes.

The new research suggests the active ingredient in Lumigan, bimatoprost, has the same effect on the scalp as tests identified a previously unknown molecular signalling pathway linked to hair growth from follicles.

Preliminary trials are now under way to see whether bimatoprost can reverse hair loss in both men and women. If successful, it may not be long before the drug is re-marketed as a baldness treatment.

Lead scientist Professor Valerie Randall, from the University of Bradford, said: "Bimatoprost is known to stimulate eyelash growth and is already used clinically for this purpose. We wanted to see whether it would have the same effect on scalp hair, as the two types of follicle are very different.

"Our findings show that bimatoprost does stimulate growth in human scalp hair follicles and therefore could offer a new approach for treating hair loss disorders."

Male hormones, or androgens, can both stimulate the growth of hair on the chest and chin, and suppress it on the head.

They are responsible for classic male pattern baldness, marked by a receding hairline and expanding bald patch in the middle of the scalp, which affects around 6.5 million men in the UK.

The hormones stimulate signalling pathways linked to baldness by latching onto specific receptor molecules on cells. These are proteins that act as key-operated switches, making a cell behave in different ways.

Prof Randall acts as a consultant to Allergan Inc, which manufactures Lumigan.

Press Association

Today's news headlines, directly to your inbox every morning.

Editors Choice

Also in World News